Bausch Health Companies (BHC) Rating Repeats by Mizuho

Bausch Health Companies (BHC) Rating Repeats by Mizuho

Bausch Health Companies (NYSE:BHC)‘s stock had its “buy” rating restated by equities research analysts at Mizuho in a research note issued to investors on Monday. They currently have a $35.00 price objective on the stock. Mizuho’s price objective indicates a potential upside of 36.19% from the stock’s current price.

The analysts wrote, “We currently model $0.5M in 2018 Bryhali sales, growing to $68.0M in 2022. Bryhali is highlighted as one of the company’s significant seven” and is expected to play a role in mgmt’s goal of doubling its dermatology business over the next 5 years. We reiterate our Buy rating and $35 PT on BHC.””

Other analysts have also issued research reports about the stock. Piper Jaffray Companies upgraded shares of Bausch Health Companies from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $16.00 to $19.00 in a research note on Thursday, September 13th. Royal Bank of Canada set a $30.00 price objective on shares of Bausch Health Companies and gave the stock a “hold” rating in a research note on Monday. JPMorgan Chase & Co. increased their price objective on shares of Bausch Health Companies to $18.00 and gave the stock an “underweight” rating in a research note on Wednesday, August 8th. ValuEngine upgraded shares of Bausch Health Companies from a “sell” rating to a “hold” rating in a research note on Monday, September 24th. Finally, HC Wainwright reiterated a “hold” rating and issued a $20.00 price objective on shares of Bausch Health Companies in a research note on Friday, August 31st. Three analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $26.89.

NYSE:BHC opened at $25.70 on Monday. The firm has a market capitalization of $8.97 billion, a PE ratio of 6.75, a price-to-earnings-growth ratio of 0.37 and a beta of -0.48. Bausch Health Companies has a 1-year low of $10.94 and a 1-year high of $28.45. The company has a current ratio of 1.14, a quick ratio of 0.89 and a debt-to-equity ratio of 6.99.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Tuesday, August 7th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.81 by $0.12. The firm had revenue of $2.13 billion for the quarter, compared to analyst estimates of $2.05 billion. Bausch Health Companies had a negative net margin of 20.60% and a positive return on equity of 27.83%. Research analysts predict that Bausch Health Companies will post 3.47 EPS for the current fiscal year.

In other news, CFO Paul Herendeen purchased 10,000 shares of the stock in a transaction that occurred on Friday, September 14th. The shares were purchased at an average cost of $22.61 per share, with a total value of $226,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Joseph C. Papa purchased 30,000 shares of the stock in a transaction that occurred on Friday, September 14th. The shares were purchased at an average cost of $22.32 per share, for a total transaction of $669,600.00. The disclosure for this purchase can be found here. Insiders have purchased 165,000 shares of company stock worth $3,890,700 over the last three months. 11.54% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. NEXT Financial Group Inc purchased a new stake in Bausch Health Companies during the third quarter worth $101,000. Point View Wealth Management Inc. purchased a new stake in Bausch Health Companies during the second quarter worth $1,132,000. Marshall Wace LLP purchased a new stake in Bausch Health Companies during the second quarter worth $2,974,000. Van ECK Associates Corp purchased a new stake in Bausch Health Companies during the second quarter worth $11,494,000. Finally, Tobam purchased a new stake in Bausch Health Companies during the second quarter worth $13,886,000. 43.16% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Read More: How a Put Option Works

Related posts

Leave a Comment